EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study

Serena Yun-Chen Tsai iD, Jonathan M Gaffin, Elena B Hawryluk, Hana B Ruran, Lisa M Bartnikas, Michiko K Oyoshi, Lynda C Schneider, Wanda Phipatanakul, Kevin Sheng-Kai Ma iD

Allergy · 2024-10 · 79 (10) · 2748-2758

DOI: 10.1111/all.16265 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Allergy, online erschienen am 21.08.2024. Verfasst von Serena Yun-Chen Tsai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Comorbidity. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.

Methods

In this population‐based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedComorbidityHumansChildAdolescentMaleFemaleChild, PreschoolInfantCohort StudiesCost of IllnessInfant, NewbornTreatment OutcomePopulation Surveillance

Stichwörter der Autor:innen

adolescentsatopic dermatitisatopic marchbiologicschildrencomorbiditiesdupilumabinfectionsmental healthneurodevelopmental disorders

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pulmonary Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Division of Immunology, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pediatric Allergy, Mucosal Immunology and Biology Research Center, Massachusetts General Hospital for Children, Charlestown, Massachusetts, USA.

ORCID-Profile: Serena Yun-Chen Tsai, Kevin Sheng-Kai Ma

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Tsai, S. Y., Gaffin, J. M., Hawryluk, E. B., Ruran, H. B., Bartnikas, L. M., Oyoshi, M. K., Schneider, L. C., Phipatanakul, W., & Ma, K. S. (2024). Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study. Allergy, 79(10), 2748-2758. https://doi.org/10.1111/all.16265

Vancouver

Tsai SY, Gaffin JM, Hawryluk EB, Ruran HB, Bartnikas LM, Oyoshi MK, et al. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study. Allergy. 2024;79(10):2748-2758. doi:10.1111/all.16265

BibTeX
@article{Tsai2024,
  author = {Tsai, Serena Yun-Chen and Gaffin, Jonathan M and Hawryluk, Elena B and Ruran, Hana B and Bartnikas, Lisa M and Oyoshi, Michiko K and Schneider, Lynda C and Phipatanakul, Wanda and Ma, Kevin Sheng-Kai},
  title = {Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {10},
  pages = {2748--2758},
  doi = {10.1111/all.16265}
}
Kostenlos starten →